Abstract
Acute rejection of the transplanted kidney is a leading cause of graft failure in renal transplant recipients. Early clinical diagnosis of rejection in these patients is difficult because other processes such as drug toxicity and infection can diminish graft function, elevate serum creatinine, and mimic rejection. Recently, we had begun testing a new peripheral blood assay for the diagnosis of rejection among solid organ allograft recipients. A significant increase in inducible interleukin-2 receptor (IL2R) expression on CD8 lymphocytes from hepatic allograft recipients was observed during periods of rejection versus quiescence (37±5 vs 9±2; p<0.001) documented by serial liver biopsies (1). In this study, we obtained peripheral blood from ten renal allograft recipients at least bi-weekly post-transplant to determine the predictive value of monitoring inducible IL2R on CD8 lymphocytes.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call